News

Nona Biosciences Announces Strategic Collaboration Agreement with PharmaEssentia Innovation Research Center

by

CAMBRIDGE, Mass., May 11, 2023 /PRNewswire/ — Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge technology innovation and provider of integrated solutions from “Idea to IND” (I to I™), announced today it has entered into a strategic collaboration agreement with Massachusetts-based PharmaEssentia Innovation Research Center (PIRC) on Nona’s proprietary Harbour Mice® fully … Read more

WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2023 RESULTS

by

Starts off year with significant commercial momentum toward focus on delivering robust year-over-year revenue growth for 2023 Previous steps taken to further optimize Willow’s business, focus on near-term revenue generation and reduce cash burn are paying off MOUNTAIN VIEW, Calif., May 11, 2023 /PRNewswire/ – Willow Biosciences Inc. (“Willow” or the “Company“) (TSX: WLLW) (OTCQB: CANSF), a leading … Read more

Sector is Expected to Reach $25.7 Billion by 2031 at a CAGR of 13.4%

by

DUBLIN, May 11, 2023 /PRNewswire/ — The “Global Cystic Fibrosis Treatment Market Report and Forecast 2023-2031” report has been added to  ResearchAndMarkets.com’s offering. The global cystic fibrosis treatment market size was valued at USD 8.3 billion in 2022 and is projected to grow at a CAGR of 13.4% during the forecast period of 2023-2031 to reach … Read more

Advanced Pharmacovigilance Training Course (London, United Kingdom

by

DUBLIN , May 11, 2023 /PRNewswire/ — The “Advanced Pharmacovigilance Training Course” conference has been added to  ResearchAndMarkets.com’s offering. Pharmacovigilance has undergone rapid regulatory change in recent years, which has resulted in a complex range of safety and risk assessment activities to perform. This three-day course is designed for those with at least two years of knowledge … Read more

Deals, Key Players and Financials

by

Dublin, May 11, 2023 /PRNewswire/ — The “Global Stem Cell Partnering Terms and Agreements 2010-2023” report has been added to  ResearchAndMarkets.com’s offering. The Global Stem Cell Partnering Terms and Agreements 2010-2023 report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies. Trends … Read more

Comprehensive Details on Deals by the World’s Leading Healthcare Companies

by

DUBLIN, May 11, 2023 /PRNewswire/ — The “Global Antibody Partnering Terms and Agreements 2016-2023” report has been added to  ResearchAndMarkets.com’s offering. The Global Antibody Partnering Terms and Agreements 2016 to 2023 report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the world’s leading healthcare companies. The report provides … Read more

Rising Awareness About Infection Prevention and Control Measures Drives Growth

by

DUBLIN, May 11, 2023 /PRNewswire/ — The “Global Hospital-Acquired Infection Treatment Market Report and Forecast 2023-2031” report has been added to  ResearchAndMarkets.com’s offering. The global hospital-acquired infection treatment market size was valued at USD 15.31 billion in 2022 and is projected to grow at a CAGR of 4.2% during the forecast period of 2023-2031 to … Read more

Nefecon Included in the Reimbursement Drug List of “Beijing Puhui Health Insurance Program” as a First-in-Disease Therapy for IgA Nephropathy

by

SHANGHAI, May 11, 2023 /PRNewswire/ — An imported version of Nefecon (budesonide) delayed release capsule has been added to the 2023 New Reimbursement Drug List of Specialized Medicines of the “Beijing Puhui Health Insurance Program.” Nefecon is a first-in-disease treatment for adults with primary immunoglobulin A nephropathy (IgAN). Nefecon has been approved by the United States Food … Read more

La FDA aprueba el primer medicamento para tratar los síntomas de agitación asociados con la demencia debida a la enfermedad de Alzheimer

by

In English SILVER SPRING, Md., 11 de mayo de 2023 /PRNewswire-HISPANIC PR WIRE/ — Hoy, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en inglés) otorgó la aprobación complementaria para los comprimidos orales de Rexulti (brexpiprazol) para el tratamiento de la agitación asociada con la demencia debido a la enfermedad de Alzheimer. … Read more

La FDA finaliza la transición para recomendar una evaluación de riesgos individual a fin de determinar la elegibilidad para donaciones de sangre

by

In English  SILVER SPRING, Md., 11 de mayo de 2023 /PRNewswire-HISPANIC PR WIRE/ — Hoy, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en inglés) finalizó las recomendaciones para evaluar la elegibilidad de los donantes de sangre mediante un conjunto de preguntas individuales basadas en el riesgo para reducir el riesgo … Read more